Metsera, Inc. Responds to Pfizer’s Litigation Claims
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Metsera, Inc. ( (MTSR) ) is now available.
On November 3, 2025, Metsera, Inc., a Delaware corporation, issued a statement in response to litigation filed against the company by Pfizer Inc. Metsera claims that Pfizer is attempting to acquire the company at a lower price than Novo Nordisk and intends to address Pfizer’s litigation arguments in court. The ongoing legal dispute and potential acquisition have significant implications for Metsera’s market positioning and shareholder interests.
The most recent analyst rating on (MTSR) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Metsera, Inc. stock, see the MTSR Stock Forecast page.
Spark’s Take on MTSR Stock
According to Spark, TipRanks’ AI Analyst, MTSR is a Underperform.
Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock’s potential.
To see Spark’s full report on MTSR stock, click here.
More about Metsera, Inc.
Average Trading Volume: 2,217,999
Technical Sentiment Signal: Strong Buy
Current Market Cap: $6.64B
For a thorough assessment of MTSR stock, go to TipRanks’ Stock Analysis page.
